Abstract
Background The global debate on the efficacy of hydroxychloroquine (HCQ) on COVID-19 has gone far beyond the scientific framework and has been highly politicized. These issues immediately invested the debate on HCQ and made it an object of particular crystallization. This study analyzes, through the Malian press, the echo of this debate in the national background.
Methods Mixed methods design, based on a review of 452 articles about COVID-19 published by six major Malian newspapers, from January 1st to July 31st 2020. Results of a content analysis with WORDSTAT8 software were further explained by a thematic qualitative analysis using and deductive-indictive approach.
Results The debate on HCQ has had very little echo in the Malian press despite some interest, because of a lack of anchoring and thus of a “response” at the national level. The national health authorities, who adopted the treatment as part of clinical trials, and the press, stayed away from both the medical and the “ideological” components of the debate, despite these a priori directly involved a country like Mali.
Conclusions The paper sheds light on the issues at stake in the HCQ debate based on a case study of an atypical country in terms of impacts of Covid-19. The governance of COVID helped crystallize political opposition to the presidential regime leading to a coup in August.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Canadian Institute of Health Research grant number DC0190GP, the French National Research Agency (ANR Flash Covid 2019) grant number ANR-20-COVI-0001-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Kate KZ Zinszer: Tel: +1 (514) 679-2995; E-mail: kate.zinszer{at}umontreal.ca
Krystelle KA Abalovi: Tel: +1 (514) 679-2995; E-mail: krystelle.abalovi{at}umontreal.ca
Nathan NP Peiffer-Smadja: Tel: +33 6 18 66 26 38; E-mail: nathan.peiffer-smadja{at}inserm.fr
Abdourahmane AC Coulibaly: Tel: +223 69 31 53 93; E-mail: coulibalyabdourahmane{at}gmail.com
Adrien AS Saucier: Tel: +1 (514) 679-2995; E-mail: adrien.saucier1{at}gmail.com
Valéry VR Ridde: Tel: +221 77 790 25 55; E-mail: valery.ridde{at}ird.fr
Data Availability
All data produced in the present study are available upon reasonable request to the authors